https://www.sciencedirect.com/science/article/pii/S0753332220307757
- Marketed drugs exhibit modest antiviral activity via the mechanism not necessarily the protein
- Ex. chloroquine, hydroxychloroquine, azithromycin
- CADs (catatonic amphiphilic drugs) have potential anti-inflammatory effects

Pomona College

Santa Clara University

Previously used drugs approved by the FDA have been repurposed in order to be tested against COVID-19. However, clinical trials are underway for several anti-malarial drugs in order to test their effects against the disease.

In silico approaches that are currently used for drug repurposing, including molecular docking, molecular dynamics, and computational chemistry, constitute valuable tools to aid preclinical and clinical studies of nanomaterials directed for disease treatment. 


Drug re-purposing against COVID-19

Ulf Norinder, Astrud Tuck, Kalle Norgren, Vesna Munic Kos, Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19, Biomedicine & Pharmacotherapy, Volume 130, 2020, 110582, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2020.110582. (http://www.sciencedirect.com/science/article/pii/S0753332220307757)

Learn Before

Related